AnaptysBio (ANAB)


Market Price (11/22/2026): $46.64 | Market Cap: $1.4 BilSector: Health Care | Industry: Biotechnology

AnaptysBio (ANAB)


Market Price (11/22/2026): $46.64
Market Cap: $1.4 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -10%

Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 95%

Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 111%

Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 15%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 15%

Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -31%

Megatrend and thematic drivers
Megatrends include Precision Medicine. Themes include Biopharmaceutical R&D, and Targeted Therapies.

Meaningful short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 10.79, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 17%

Expensive valuation multiples
P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 40x, P/EPrice/Earnings or Price/(Net Income) is 89x

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -4.2%

Key risks
ANAB key risks include [1] a history of significant clinical trial failures and discontinued programs, Show more.

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -10%
1 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 95%
2 Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 111%
3 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 15%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 15%
4 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -31%
5 Megatrend and thematic drivers
Megatrends include Precision Medicine. Themes include Biopharmaceutical R&D, and Targeted Therapies.
6 Meaningful short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 10.79, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 17%
7 Expensive valuation multiples
P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 40x, P/EPrice/Earnings or Price/(Net Income) is 89x
8 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -4.2%
9 Key risks
ANAB key risks include [1] a history of significant clinical trial failures and discontinued programs, Show more.

ANAB in ETFs

Weight = ANAB's share of each fund

VTI0.00%
ITOT0.00%
IWM0.03%
XBI0.30%
IBB0.09%
IWO0.06%
VTWO0.03%
SCHA0.02%
+5 more covered ETFs

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/20/2026

Down 34.9% from its Jul 13 high to Oct 20 (S&P 500 up 2.9%)
The stock saw a significant decline over this period without company news. This downturn included sharp drops on July 15 and July 20.

Nov 13: down 3.2% the day after its Nov 12 earnings report (S&P 500 down 0.4%)
The stock declined following the release of its fiscal first quarter 2027 financial results. AnaptysBio reported diluted EPS of $0.11, missing Zacks Consensus Estimates for earnings and revenue.

Show more
Prices as of 11/20/2026

Down 34.9% from its Jul 13 high to Oct 20 (S&P 500 up 2.9%)
The stock saw a significant decline over this period without company news. This downturn included sharp drops on July 15 and July 20.

Nov 13: down 3.2% the day after its Nov 12 earnings report (S&P 500 down 0.4%)
The stock declined following the release of its fiscal first quarter 2027 financial results. AnaptysBio reported diluted EPS of $0.11, missing Zacks Consensus Estimates for earnings and revenue.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -12.6% change in ANAB stock from 7/31/2026 to 11/21/2026 was primarily driven by a -12.1% change in the company's P/S Multiple.
(LTM values as of)731202611212026Change
Stock Price ($)53.3646.63-12.6%
Change Contribution By: 
Total Revenues ($ Mil)2322403.4%
P/S Multiple6.65.8-12.1%
Shares Outstanding (Mil)2930-3.9%
Cumulative Contribution-12.6%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/21/2026
ReturnCorrelation
ANAB-12.6% 
Market (SPY)-7.4%30.7%
Sector (XLV)9.5%1.9%

Fundamental Drivers

The -29.1% change in ANAB stock from 4/30/2026 to 11/21/2026 was primarily driven by a -25.6% change in the company's P/S Multiple.
(LTM values as of)430202611212026Change
Stock Price ($)65.7346.63-29.1%
Change Contribution By: 
Total Revenues ($ Mil)2352402.5%
P/S Multiple7.85.8-25.6%
Shares Outstanding (Mil)2830-6.9%
Cumulative Contribution-29.1%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/21/2026
ReturnCorrelation
ANAB-29.1% 
Market (SPY)-3.5%16.5%
Sector (XLV)22.4%9.7%

Fundamental Drivers

The 27.5% change in ANAB stock from 10/31/2025 to 11/21/2026 was primarily driven by a 95.2% change in the company's Total Revenues ($ Mil).
(LTM values as of)1031202511212026Change
Stock Price ($)36.5846.6327.5%
Change Contribution By: 
Total Revenues ($ Mil)12324095.2%
P/S Multiple8.65.8-32.3%
Shares Outstanding (Mil)2930-3.5%
Cumulative Contribution27.5%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/21/2026
ReturnCorrelation
ANAB27.5% 
Market (SPY)2.2%19.2%
Sector (XLV)24.9%12.8%

Fundamental Drivers

The 185.9% change in ANAB stock from 10/31/2023 to 11/21/2026 was primarily driven by a 1758.5% change in the company's Total Revenues ($ Mil).
(LTM values as of)1031202311212026Change
Stock Price ($)16.3146.63185.9%
Change Contribution By: 
Total Revenues ($ Mil)132401758.5%
P/S Multiple33.65.8-82.8%
Shares Outstanding (Mil)2730-10.8%
Cumulative Contribution185.9%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2023 to 11/21/2026
ReturnCorrelation
ANAB185.9% 
Market (SPY)71.0%18.0%
Sector (XLV)49.6%19.3%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
ANAB Return62%-11%-31%-38%266%-4%117%
Peers Return8%7%5%14%45%7%115%
S&P 500 Return27%-19%24%23%16%8%97%

Monthly Win Rates [3]
ANAB Win Rate75%50%25%58%75%45% 
Peers Win Rate53%57%52%47%67%45% 
S&P 500 Win Rate75%42%67%75%67%36% 

Max Drawdowns [4]
ANAB Max Drawdown-46%-48%-55%-68%-31%-35% 
Peers Max Drawdown-35%-35%-35%-29%-33%-30% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, REGN, ALNY, INCY, KYMR.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/20/2026 (YTD)

How Low Can It Go

EventANABS&P 500
2025 US Tariff Shock
  % Loss-25.3%-18.8%
  % Gain to Breakeven33.9%23.1%
  Time to Breakeven45 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-21.4%-9.5%
  % Gain to Breakeven27.1%10.5%
  Time to Breakeven15 days24 days
2023 SVB Regional Banking Crisis
  % Loss-29.4%-6.7%
  % Gain to Breakeven41.6%7.1%
  Time to Breakeven263 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-47.9%-24.5%
  % Gain to Breakeven92.1%32.4%
  Time to Breakeven782 days427 days
2020 COVID-19 Crash
  % Loss-17.5%-33.7%
  % Gain to Breakeven21.1%50.9%
  Time to Breakeven22 days140 days

Compare to VRTX, REGN, ALNY, INCY, KYMR

In The Past

AnaptysBio's stock fell -25.3% during the 2025 US Tariff Shock. Such a loss loss requires a 33.9% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventANABS&P 500
2025 US Tariff Shock
  % Loss-25.3%-18.8%
  % Gain to Breakeven33.9%23.1%
  Time to Breakeven45 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-21.4%-9.5%
  % Gain to Breakeven27.1%10.5%
  Time to Breakeven15 days24 days
2023 SVB Regional Banking Crisis
  % Loss-29.4%-6.7%
  % Gain to Breakeven41.6%7.1%
  Time to Breakeven263 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-47.9%-24.5%
  % Gain to Breakeven92.1%32.4%
  Time to Breakeven782 days427 days

Compare to VRTX, REGN, ALNY, INCY, KYMR

In The Past

AnaptysBio's stock fell -25.3% during the 2025 US Tariff Shock. Such a loss loss requires a 33.9% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About AnaptysBio (ANAB)

AnaptysBio, Inc. (ANAB) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapeutic product candidates. The company primarily focuses on creating antibody-based treatments for conditions falling under the categories of inflammation and immuno-oncology, aiming to address significant unmet medical needs in these areas.

The company's pipeline features several key antibody programs. Imsidolimab is an antibody designed to inhibit the interleukin-36 receptor, targeting a range of dermatological inflammatory diseases. Rosnilimab is an anti-PD-1 agonist antibody program engineered to augment PD-1 signaling, intending to suppress T-cell driven human inflammatory diseases. Furthermore, ANB032 is an anti-BTLA modulator antibody with potential applications in inflammatory diseases linked to lymphoid and myeloid immune cell dysregulation. AnaptysBio also leverages its expertise through collaborations, advancing additional antibody programs with partners such as GlaxoSmithKline and Bristol-Myers Squibb.

AnaptysBio's primary market encompasses patients suffering from various inflammatory and immuno-oncology conditions, particularly those involving dermatological issues and immune cell dysregulation. As a clinical-stage company, its "products" are its drug candidates in development, with the ultimate goal of providing new therapeutic options to healthcare providers and patients within these specialized medical fields.

AI Analysis | Feedback

Here are 1-3 brief analogies for AnaptysBio:

AnaptysBio is like an early-stage Genentech, developing novel antibody therapies for inflammatory and immune diseases.

AnaptysBio is like a specialized AbbVie, but for emerging antibody treatments targeting inflammation.

AI Analysis | Feedback

AnaptysBio Major Products:

  • Imsidolimab: An antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases.
  • Rosnilimab: An anti-PD-1 agonist antibody program designed to augment PD-1 signaling to suppress T-cell driven human inflammatory diseases.
  • ANB032: An anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.
  • Collaboration Antibody Programs: Various antibody programs advanced to preclinical and clinical milestones under collaborations with partners like GlaxoSmithKline and Bristol-Myers Squibb.

AI Analysis | Feedback

Major Customers of AnaptysBio (ANAB)

AnaptysBio, Inc. is a clinical-stage biotechnology company that develops therapeutic product candidates and antibody programs. Its business model primarily involves collaborations and licensing agreements with other companies and research institutions, rather than selling products directly to individuals. Based on the provided information, its major customers and partners include:
  • GlaxoSmithKline, Inc. (Symbol: GSK)
  • Bristol-Myers Squibb (Symbol: BMY)
  • United Kingdom Research and Innovation
  • Millipore Corporation

AI Analysis | Feedback

null

AI Analysis | Feedback

```html

Daniel Faga, President & CEO

Daniel Faga has served as AnaptysBio's President and Chief Executive Officer since March 2022, transitioning from interim to full CEO in August 2023. He brings over 20 years of operating and advisory experience in the life sciences industry. Prior to joining AnaptysBio, Mr. Faga was Chief Operating Officer at Mirati Therapeutics. He also served as Chief Business Officer at Spark Therapeutics until its acquisition by Roche. Earlier in his career, he was a managing director and founding member of Centerview Partners' healthcare advisory practice, and held roles in healthcare investment banking at Merrill Lynch and management consulting at PRTM.

Dennis Mulroy, Chief Financial Officer

Dennis Mulroy joined AnaptysBio as Chief Financial Officer in July 2020, leading the company's finance, accounting, reporting, and investor relations functions. His prior experience includes serving as Chief Financial Officer for several companies, including La Jolla Pharmaceutical Company, Taxus Cardium Pharmaceuticals Group, Molecular Imaging, and SeraCare Life Sciences. Mr. Mulroy began his career as a Certified Public Accountant with Ernst & Young LLP.

Paul F. Lizzul, M.D., Ph.D., M.P.H, M.B.A., Chief Medical Officer

Paul F. Lizzul serves as the Chief Medical Officer at AnaptysBio.

Eric Loumeau, J.D., Chief Legal Officer

Eric Loumeau is the Chief Legal Officer at AnaptysBio, with over 20 years of experience in the biotech sector. His expertise spans corporate finance, including raising over $5 billion in public and private securities offerings, and mergers and acquisitions. Before his current role, Mr. Loumeau was General Counsel and Chief Compliance Officer at Otonomy, Inc. He also previously served as Chief Financial Officer of Rempex Pharmaceuticals, Inc., and became Vice President of Legal Affairs following its acquisition by The Medicines Company. Mr. Loumeau's background also includes serving as General Counsel at Hollis-Eden Pharmaceuticals, Inc., and practicing securities and corporate law at various national law firms.

Ben Stone, Chief Business Officer

Ben Stone holds the position of Chief Business Officer at AnaptysBio.

```

AI Analysis | Feedback

The key risks to AnaptysBio (ANAB) primarily revolve around the inherent uncertainties of clinical-stage biotechnology development, its financial needs, and its reliance on collaborations.

  1. Clinical Trial Success and Regulatory Approval: As a clinical-stage biotechnology company, AnaptysBio faces significant risks related to the development and commercialization of its product candidates. There is a risk of potential failures, delays, or encountering significant adverse events or toxicities in ongoing and planned clinical trials, which could adversely affect the commercial viability of its products and inhibit regulatory approval or market acceptance. Even if clinical trials are successful, there is no guarantee that the company will obtain the necessary regulatory approvals in a timely manner, or at all, in the United States or foreign jurisdictions. Furthermore, product candidates like Imsidolimab (IL-36R inhibitor) require careful evaluation for long-term safety, potential immunogenicity, and maintaining a balance between efficacy and safety. The development of Rosnilimab (anti-PD-1 agonist) and ANB032 (anti-BTLA modulator) also carries risks related to adverse events, patient selection, and the complex mechanisms of immune modulation.
  2. Funding and Commercialization Challenges: AnaptysBio has limited operating revenue and a history of operational losses, necessitating additional capital to finance its extensive and costly research, development, and commercialization efforts. There is a risk that this capital may not be available on acceptable terms or at all, which could jeopardize ongoing projects and operational stability. Even with regulatory approval, the company faces significant challenges in commercializing its products, as it has no history of independently commercializing biotechnology products. This includes risks related to market acceptance of its product candidates, intense competition from other existing or developing therapies, and the ability to build internal sales and marketing capabilities or secure suitable third-party agreements. The decision to seek a partnership for Rosnilimab rather than advancing to a pivotal trial independently may also suggest uncertainties regarding its commercial potential.
  3. Reliance on Collaborations and Business Separation Risks: AnaptysBio is heavily reliant on its collaborations, such as the one with GlaxoSmithKline (GSK), and any disruption or underperformance in these relationships could materially and adversely affect its business. Litigation with a GSK unit concerning a cancer therapy deal has been identified as a risk. The timing and ability of collaborators to successfully develop and commercialize partnered product candidates is a key external risk factor. Additionally, AnaptysBio has announced plans to separate its biopharma operations into a new public company, First Tracks Biotherapeutics. This separation process carries inherent risks and uncertainties, including those related to its structure, timing, taxation, costs, and the ability to attract and retain key talent across the newly independent entities, which could materially impact shareholder value.

AI Analysis | Feedback

null

AI Analysis | Feedback

Imsidolimab (IL-36R inhibitor)

  • For Generalized Pustular Psoriasis (GPP), the global market is projected to reach USD 36.9 billion by 2035.

Rosnilimab (anti-PD-1 agonist antibody)

  • For Rheumatoid Arthritis (RA), the U.S. market is valued at more than $20 billion. Global sales for the RA market reached $42.3 billion in 2024, with the U.S. market accounting for $25.3 billion.
  • For Ulcerative Colitis (UC), the market size is around $6 billion.
  • As a PD-1 agonist, Rosnilimab operates within the broader global PD-1/PD-L1 inhibitors market, which was valued at approximately USD 59.46 billion in 2025 and is projected to reach USD 146.02 billion by 2035. The PD-L1 inhibitors market in the 7MM (United States, EU4, UK, and Japan) was approximately USD 36 billion in 2023, with the United States holding the largest share at nearly USD 26 billion in 2023.

ANB032 (anti-BTLA modulator antibody)

  • For Atopic Dermatitis (AD), the market size is around $16 billion.
  • As a BTLA agonist, ANB032 is part of the global immunomodulators market, which was valued at USD 217.5 million in 2023 and is projected to grow to USD 1,237.66 billion by 2034, exhibiting a compound annual growth rate (CAGR) of 14.6%. The United States immunomodulator market alone is projected to reach USD 32 billion by 2034.

AI Analysis | Feedback

AnaptysBio, Inc. (ANAB) is expected to have several key drivers for future revenue growth over the next two to three years, primarily stemming from its existing collaborations and the advancement of its clinical pipeline. It is important to note that AnaptysBio is planning a business separation in the second quarter of 2026, which will create two independent public companies: one focused on managing royalty streams (retaining the AnaptysBio name and ANAB symbol) and another, First Tracks Biotherapeutics, dedicated to advancing the clinical immunology pipeline. Here are the primary expected drivers of future revenue growth:
  • Growing Royalties from Jemperli (dostarlimab): AnaptysBio is entitled to royalties from GSK's oncology drug, Jemperli, a PD-1 antagonist. Jemperli's sales have shown significant growth, with a Q4 2025 annualized run rate of approximately $1.4 billion. GSK anticipates Jemperli's peak sales to exceed $2.7 billion as early as 2029, which is expected to translate into over $390 million in annualized royalties for AnaptysBio. This growing royalty stream will be a significant revenue contributor for the royalty-focused AnaptysBio entity post-spin-off.
  • Commercialization of Imsidolimab and Associated Royalties/Milestones: AnaptysBio has an exclusive global license agreement with Vanda Pharmaceuticals for the development and commercialization of imsidolimab, an IL-36R antagonist for Generalized Pustular Psoriasis (GPP). Imsidolimab has successfully completed two Phase 3 studies, and Vanda is preparing regulatory applications for the US and Europe in 2025. The FDA's Prescription Drug User Fee Act (PDUFA) target action date for imsidolimab in GPP is December 12, 2026. AnaptysBio is eligible to receive a 10% royalty on global net sales of imsidolimab and up to $35 million in future regulatory approval and sales milestones. This represents a new revenue stream for the royalty-focused AnaptysBio after the spin-off.
  • Advancement of Rosnilimab in Rheumatoid Arthritis (RA): Rosnilimab, an anti-PD-1 agonist antibody, is a lead program in AnaptysBio's wholly-owned pipeline that will be part of the spun-off First Tracks Biotherapeutics. It has demonstrated positive Phase 2b data in rheumatoid arthritis, with updated clinical and translational data presented in June 2025. The company is assessing the best path to move this program into Phase 3 development and is meeting with the FDA in Q1 2026 to discuss this. Successful progression through later-stage clinical trials will be a key driver of increased valuation and potential future revenue generation, although commercialization is likely beyond the immediate 2-3 year timeframe.
  • Progress of ANB033 in Celiac Disease and Eosinophilic Esophagitis (EoE): ANB033, a CD122 antagonist, is another promising asset within the pipeline that will transition to First Tracks Biotherapeutics. It is currently undergoing Phase 1b trials for celiac disease and has initiated a trial cohort in eosinophilic esophagitis (EoE). Initial data for the EoE trial is anticipated in 2027. Positive clinical trial results and continued advancement of ANB033 in these indications, particularly given its "pipeline-in-a-product potential," could significantly contribute to the long-term value and future revenue of the biopharma entity.

AI Analysis | Feedback

Share Repurchases

  • AnaptysBio authorized an amended stock repurchase plan of $100 million in November 2025, adding to the $6.4 million remaining from a prior $75 million program.
  • Under its previous repurchase program, AnaptysBio repurchased 3,443,188 shares of common stock for $68.6 million, representing 11.2% of outstanding shares before the program's commencement.
  • The expanded stock repurchase program is scheduled to expire on March 31, 2026.

Inbound Investments

  • AnaptysBio received a one-time $75 million commercial sales milestone payment from GSK in December 2025, as Jemperli achieved $1 billion in worldwide net sales.
  • The company received $15 million from Vanda Pharmaceuticals in 2025 for the license of imsidolimab.
  • AnaptysBio maintains financial collaborations for out-licensed therapeutic antibodies, including Jemperli with GSK and imsidolimab with Vanda Pharmaceuticals, which provide royalty and milestone payments.

Capital Expenditures

  • In the last 12 months (as of March 9, 2026), AnaptysBio reported capital expenditures of -$87,000.
  • Property and equipment, net, decreased from $1.849 million in 2024 to $1.370 million in 2025.

Better Bets vs. AnaptysBio (ANAB)

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

ANABVRTXREGNALNYINCYKYMRMedian
NameAnaptysB.Vertex P.Regenero.Alnylam .Incyte Kymera T. 
Mkt Price46.64515.66917.00144.06115.00124.10134.08
Mkt Cap1.4130.793.319.323.412.421.3
Rev LTM24012,95216,8965,0136,0111025,512
Op Inc LTM2664,2885,134978701-405839
FCF LTM353,2023,628806680-289743
FCF 3Y Avg-741,7293,609330623-222476
CFO LTM353,6954,846956745-288850
CFO 3Y Avg-742,1904,721408699-213554

Growth & Margins

ANABVRTXREGNALNYINCYKYMRMedian
NameAnaptysB.Vertex P.Regenero.Alnylam .Incyte Kymera T. 
Rev Chg LTM95.2%10.5%18.6%56.2%24.9%133.8%40.5%
Rev Chg 3Y Avg178.3%10.3%9.1%43.6%18.6%56.9%31.1%
Rev Chg Q36.0%11.8%36.3%16.7%14.0%-100.0%15.4%
QoQ Delta Rev Chg LTM3.4%2.9%8.8%4.4%3.3%-2.6%3.4%
Op Inc Chg LTM180.0%4,760.7%34.8%269.3%-44.2%-23.3%107.4%
Op Inc Chg 3Y Avg110.2%1,548.2%6.9%185.6%3,491.5%-32.4%147.9%
Op Mgn LTM110.6%33.1%30.4%19.5%11.7%-396.0%24.9%
Op Mgn 3Y Avg-107.0%22.4%28.9%6.3%12.7%-456.7%9.5%
QoQ Delta Op Mgn LTM16.0%-4.8%3.5%-1.3%-20.0%-66.2%-3.1%
CFO/Rev LTM14.6%28.5%28.7%19.1%12.4%-281.3%16.9%
CFO/Rev 3Y Avg-171.2%17.4%31.6%9.5%13.6%-314.9%11.5%
FCF/Rev LTM14.6%24.7%21.5%16.1%11.3%-282.6%15.4%
FCF/Rev 3Y Avg-171.9%13.5%24.2%7.4%12.0%-326.1%9.7%

Valuation

ANABVRTXREGNALNYINCYKYMRMedian
NameAnaptysB.Vertex P.Regenero.Alnylam .Incyte Kymera T. 
Mkt Cap1.4130.793.319.323.412.421.3
P/S5.810.15.53.83.9121.55.7
P/Op Inc5.230.518.219.733.3-30.718.9
P/EBIT5.128.716.317.829.3-35.617.0
P/E88.632.919.47.357.9-35.626.1
P/CFO39.635.419.220.231.4-43.225.8
Total Yield1.1%3.0%5.6%13.8%1.7%-3.0%2.4%
Dividend Yield0.0%0.0%0.4%0.0%0.0%0.0%0.0%
FCF Yield 3Y Avg-8.8%1.5%4.8%0.9%3.3%-3.8%1.2%
D/E0.00.00.00.10.00.00.0
Net D/E-0.10.0-0.1-0.1-0.2-0.1-0.1

Returns

ANABVRTXREGNALNYINCYKYMRMedian
NameAnaptysB.Vertex P.Regenero.Alnylam .Incyte Kymera T. 
1M Rtn-2.7%-1.7%13.9%-36.0%1.4%10.2%-0.2%
3M Rtn-19.2%-5.9%10.1%-39.0%-10.0%3.6%-8.0%
6M Rtn-21.9%18.7%43.8%-51.6%18.4%57.3%18.5%
12M Rtn23.8%22.1%25.0%-67.7%13.0%92.0%23.0%
3Y Rtn229.1%45.3%16.0%-12.0%116.0%554.5%80.7%
1M Excs Rtn0.2%-0.4%15.3%-33.4%1.6%15.4%0.9%
3M Excs Rtn-17.1%-2.7%13.9%-35.9%-7.0%5.8%-4.9%
6M Excs Rtn-21.1%19.4%44.6%-50.8%19.1%58.1%19.3%
12M Excs Rtn14.4%10.8%19.7%-80.4%1.8%78.9%12.6%
3Y Excs Rtn159.4%-17.2%-47.5%-80.6%44.2%516.4%13.5%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil20262025202420232022
Royalty Management532359117 
Biopharma 000 
Research and development activities to deliver immunology therapeutics for autoimmune and    10
Total53235911710


Operating Income by Segment
$ Mil20262025202420232022
Royalty Management3222766-46 
Biopharma -179-181-118 
Research and development activities to deliver immunology therapeutics for autoimmune and    -115
Total3248-115-164-115


Net Income by Segment
$ Mil20262025202420232022
Royalty Management17615318-57 
Biopharma -166-164-106 
Research and development activities to deliver immunology therapeutics for autoimmune and    -129
Total176-13-145-164-129


Price Behavior

null
ANAB Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta0.770.880.890.510.930.85
Up Beta2.740.480.992.971.320.64
Down Beta-0.540.280.99-0.79-0.180.25
Up Capture89%53%53%-11%144%281%
Bmk +ve Days12182862130427
Stock +ve Days12192956128368
Down Capture135%169%118%79%105%106%
Bmk -ve Days10253664121325
Stock -ve Days10243570121379

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with ANAB
ANAB26.1%64.5%0.62-
Sector ETF (XLV)18.4%17.1%0.8014.7%
Equity (SPY)5.2%14.4%0.1123.9%
Gold (GLD)-13.9%29.3%-0.5210.1%
Commodities (DBC)28.2%21.5%1.05-6.9%
Real Estate (VNQ)8.6%14.3%0.332.8%
Bitcoin (BTCUSD)-35.8%43.9%-0.8913.4%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with ANAB
ANAB7.7%66.6%0.39-
Sector ETF (XLV)7.5%15.4%0.2922.6%
Equity (SPY)9.6%17.4%0.3922.1%
Gold (GLD)13.1%19.3%0.533.7%
Commodities (DBC)6.6%19.6%0.22-4.4%
Real Estate (VNQ)0.5%19.0%-0.0817.6%
Bitcoin (BTCUSD)-1.7%51.5%0.1515.0%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with ANAB
ANAB10.8%74.9%0.49-
Sector ETF (XLV)11.4%16.8%0.5524.0%
Equity (SPY)14.1%18.1%0.6623.7%
Gold (GLD)10.4%16.6%0.503.2%
Commodities (DBC)7.2%18.2%0.315.4%
Real Estate (VNQ)5.9%20.7%0.2417.4%
Bitcoin (BTCUSD)55.4%66.3%0.959.4%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity5.1 Mil
Short Interest: % Change Since 10152026-6.3%
Average Daily Volume0.5 Mil
Days-to-Cover Short Interest10.8 days
Basic Shares Quantity29.8 Mil
Short % of Basic Shares16.9%

Earnings Returns History

Updated 11/22/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/12/2026-3.2%-0.8% 
5/12/2026-4.4%-8.9%-17.3%
3/3/202614.6%17.4%7.4%
1/9/20269.8%2.3%12.5%
11/4/20253.6%-3.4%27.7%
8/6/2025-9.6%-8.1%-2.8%
5/5/2025-2.9%-3.4%2.6%
2/27/20252.6%0.0%15.5%
...
SUMMARY STATS   
# Positive121212
# Negative151514
Median Positive7.8%4.4%12.3%
Median Negative-3.2%-5.4%-12.5%
Max Positive14.6%17.4%27.7%
Max Negative-23.1%-23.6%-18.5%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/12/2026-3.2%-0.8% 
5/12/2026-4.4%-8.9%-17.3%
3/3/202614.6%17.4%7.4%
1/9/20269.8%2.3%12.5%
11/4/20253.6%-3.4%27.7%
8/6/2025-9.6%-8.1%-2.8%
5/5/2025-2.9%-3.4%2.6%
2/27/20252.6%0.0%15.5%
11/5/202411.7%8.1%19.0%
8/5/2024-0.9%4.3%14.7%
5/9/2024-10.8%-2.9%-10.0%
3/11/202411.6%-0.8%-5.1%
1/5/20245.3%8.1%12.1%
11/2/20238.2%-8.0%-3.8%
8/7/20232.7%4.4%7.9%
5/11/2023-6.3%-8.8%-9.6%
3/1/2023-2.4%-6.4%-15.8%
1/5/2023-23.1%-23.6%-14.5%
11/8/2022-0.9%1.3%-4.6%
8/8/2022-5.6%4.4%7.7%
5/4/2022-11.1%-12.3%-13.9%
3/7/2022-0.8%-5.4%-15.9%
11/4/20217.5%-3.6%-11.2%
8/9/2021-2.4%-0.8%13.4%
5/4/20213.7%9.6%1.4%
2/25/202110.5%8.3%-18.4%
11/4/2020-1.3%0.9%-18.5%
SUMMARY STATS   
# Positive121212
# Negative151514
Median Positive7.8%4.4%12.3%
Median Negative-3.2%-5.4%-12.5%
Max Positive14.6%17.4%27.7%
Max Negative-23.1%-23.6%-18.5%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202611/12/202610-Q
06/30/202609/21/202610-KT
03/31/202605/12/202610-Q
12/31/202503/03/202610-K
09/30/202511/04/202510-Q
06/30/202508/06/202510-Q
03/31/202505/05/202510-Q
12/31/202402/27/202510-K
09/30/202411/05/202410-Q
06/30/202408/05/202410-Q
03/31/202405/09/202410-Q
12/31/202303/11/202410-K
09/30/202311/02/202310-Q
06/30/202308/07/202310-Q
03/31/202305/11/202310-Q
12/31/202203/01/202310-K
Collapse to Preview
Report DateFiling DateFiling
09/30/202611/12/202610-Q
06/30/202609/21/202610-KT
03/31/202605/12/202610-Q
12/31/202503/03/202610-K
09/30/202511/04/202510-Q
06/30/202508/06/202510-Q
03/31/202505/05/202510-Q
12/31/202402/27/202510-K
09/30/202411/05/202410-Q
06/30/202408/05/202410-Q
03/31/202405/09/202410-Q
12/31/202303/11/202410-K
09/30/202311/02/202310-Q
06/30/202308/07/202310-Q
03/31/202305/11/202310-Q
12/31/202203/01/202310-K
09/30/202211/08/202210-Q
06/30/202208/08/202210-Q
03/31/202205/04/202210-Q
12/31/202103/07/202210-K
09/30/202111/04/202110-Q
06/30/202108/09/202110-Q
03/31/202105/04/202110-Q
12/31/202002/25/202110-K
09/30/202011/04/202010-Q
06/30/202008/10/202010-Q
03/31/202005/06/202010-Q
12/31/201903/02/202010-K

Recent Forward Guidance

Updated 11/13/2026

Latest: Q1 2027 Earnings Reported 11/12/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2029 Annualized Jemperli RoyaltiesReported390.00 Mil390.00 Mil 0.0% AffirmedGuidance: 390.00 Mil for 2029
2027 Non-Recourse Debt Monetization PaydownReported 270.00 Mil    


Prior: Q1 2026 Earnings Reported 5/12/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2029 Annualized Jemperli RoyaltiesReported 390.00 Mil 0 AffirmedGuidance: 390.00 Mil for 2029
Q2 2027 Debt PaydownReported 325.00 Mil    

Q4 2025 Earnings Reported 3/3/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2029 Annualized Jemperli RoyaltiesReported 390.00 Mil 0 AffirmedGuidance: 390.00 Mil for 2031
2029 GSK Peak Sales GuidanceReported 2.70 Bil 0 AffirmedGuidance: 2.70 Bil for 2031

Insider Activity

Updated 11/18/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Ecor1, Capital, Llc See NoteBuy1118202646.54138,0936,427,111384,188,212Form
2Ecor1, Capital, Llc See NoteBuy1118202645.66152,3676,956,361370,564,941Form
3Ecor1, Capital, Llc See NoteBuy1118202645.6684,1203,841,121363,665,125Form
4Renton, HollingsDirectSell1002202649.875,000249,372548,368Form
5Schmid, John PDirectSell401202656.1120,6451,158,4511,774,403Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Ecor1, Capital, Llc See NoteBuy1118202646.54138,0936,427,111384,188,212Form
2Ecor1, Capital, Llc See NoteBuy1118202645.66152,3676,956,361370,564,941Form
3Ecor1, Capital, Llc See NoteBuy1118202645.6684,1203,841,121363,665,125Form
4Renton, HollingsDirectSell1002202649.875,000249,372548,368Form
5Schmid, John PDirectSell401202656.1120,6451,158,4511,774,403Form
6Faga, DanielPresident, CEODirectSell327202661.6117,6791,089,19930,556,279Form
7Loumeau, Eric JCHIEF LEGAL OFFICERDirectSell213202654.0010,000540,000693,090Form
8Marquet, MagdaDirectSell116202648.2311,000530,531478,925Form
9Lizzul, Paul FChief Medical OfficerDirectSell109202644.713,650163,1921,881,754Form
10Mulroy, DennisCHIEF FINANCIAL OFFICERDirectSell109202644.712,515112,446977,003Form
11Loumeau, Eric JCHIEF LEGAL OFFICERDirectSell109202644.712,21098,809573,853Form
12Faga, DanielPresident, CEODirectSell109202644.7114,281638,50421,431,470Form
13Faga, DanielPresident, CEODirectSell106202643.2615,309662,26719,819,093Form
14Mulroy, DennisCHIEF FINANCIAL OFFICERDirectSell106202643.263,363145,483619,916Form
15Lizzul, Paul FChief Medical OfficerDirectSell106202643.264,219182,5141,440,688Form
16Loumeau, Eric JCHIEF LEGAL OFFICERDirectSell106202643.262,983129,045573,238Form
17Ware, J. AnthonyDirectSell1223202549.583,900193,342477,407Form
18Lizzul, Paul FChief Medical OfficerDirectSell1223202550.001,50075,0001,348,350Form
19Mulroy, DennisCHIEF FINANCIAL OFFICERDirectSell1223202550.0010,000500,000470,050Form
20Loumeau, Eric JCHIEF LEGAL OFFICERDirectSell1223202551.0010,000510,000456,297Form
21Loumeau, Eric JCHIEF LEGAL OFFICERDirectSell1218202546.991416,626420,420Form
22Loumeau, Eric JCHIEF LEGAL OFFICERDirectSell1218202546.0010,000460,000418,048Form
23Loumeau, Eric JCHIEF LEGAL OFFICERDirectSell1218202544.8612,500560,800407,724Form
24Mulroy, DennisCHIEF FINANCIAL OFFICERDirectSell1218202544.8515,725705,333421,675Form

Investor Activity (13F)

Updated Nov 22, 2026
13F holdings as of Mar 31, 2026 (Q1 2026)

Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

Active ManagerValue% of PortfolioTotal PositionsQoQFiling
EcoR1 Capital, LLC$437.0 Mil18.7%29Hold13F
Sanofi$30.4 Mil9.0%9Hold13F
First Light Asset Management, LLC$31.4 Mil2.8%35TRIM -12.5%13F
Active Manager
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
First Light Asset Management, LLC$31.4 Mil2.8%35TRIM -12.5%13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
EcoR1 Capital, LLC$437.0 Mil18.7%29Hold13F
First Light Asset Management, LLC$31.4 Mil2.8%35TRIM -12.5%13F
Sanofi$30.4 Mil9.0%9Hold13F
Core Cache Last Updated: 11/21/2026